56073-93-9

Upstream product

• 1635-61-6 5-chloro-2-nitroaniline 
• 1126-81-4 4-acetamidothiophenol 

Downstream Products

• 19284-74-3 3,4'-diamino-4-nitrodiphenyl sulphide 
• 97849-16-6 4-(1H-Benzoimidazol-5-ylsulfanyl)-phenylamine 
• 97849-17-7 4-(2-Methyl-1H-benzoimidazol-5-ylsulfanyl)-phenylamine 
• 97849-26-8 2-amino-5⁽⁶⁾-(4-aminophenylthio)benzimidazole 
• 97849-18-8 4-(1H-Benzoimidazole-5-sulfonyl)-phenylamine 
• 97849-19-9 5-(4-Isothiocyanato-phenylsulfanyl)-1H-benzoimidazole 
• 97849-15-5 5⁽⁶⁾-(4-acetaminophenylsulphono)-2-methylbenzimidazole 
• 97849-20-2 5-(4-Isothiocyanato-phenylsulfanyl)-2-methyl-1H-benzoimidazole 
• 97849-08-6 N-[4-(1H-Benzoimidazol-5-ylsulfanyl)-phenyl]-acetamide 
• 97849-27-9 5-(4-Amino-benzenesulfonyl)-1H-benzoimidazol-2-ylamine 
• 97849-06-4 5⁽⁶⁾-(4-acetamidophenylthio)-2-methylbenzimidazole 
• 97849-21-3 5-(4-Isothiocyanato-benzenesulfonyl)-1H-benzoimidazole 
• 97849-22-4 5⁽⁶⁾-(4-isothiocyanatophenylsulphono)-2-methylbenzimidazole 
• 97849-11-1 N-[4-(1H-Benzoimidazole-5-sulfonyl)-phenyl]-acetamide 

Relevant academic research and scientific papers

Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors

We herein disclose a novel chemical series of benzimidazole-ureas as inhibitors of VEGFR-2 and TIE-2 kinase receptors, both of which are implicated in angiogenesis. Structure-activity relationship (SAR) studies elucidated a critical role for the N1 nitrogen of both the benzimidazole (segment E) and urea (segment B) moieties. The SAR results were also supported by the X-ray crystallographic elucidation of the role of the N1 nitrogen and the urea moiety when the benzimidazole-urea compounds were bound to the VEGFR-2 enzyme. The left side phenyl ring (segment A) occupies the backpocket where a 3-hydrophobic substituent was favored for TIE-2 activity.

Use of compounds for the elevation of pyruvate dehydrogenase activity

The use of compounds of the formula (I), and salts thereof; and pharmaceutically acceptable in vivo cleavable prodrugs of said compound of formula (I); and pharmaceutically acceptable salts of said compound or said prodrugs: wherein: Ring C is phenyl or a carbon linked heteroaryl ring substituted as defmed within; R1is an ortho substituent as defined within; n is 1 or 2; A—B is a linking group as defined within; R2and R3are as defined within; R4is hydroxy, hydrogen, halo, amino or methyl; in the manufacture of a medicament for use in the elevation of PDH activity in warm-blooded animals such as humans is described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are also described.

Syntheses of 2,5(6)-Disubstituted Benzimidazoles and 1,4-Disubstituted Piperazines as Potential Antiparasitic Agents

The synthesis of a series of 5(6)-benzimidazoles (13-21), 1-(7-chloroquinolin-4-yl)-4-piperazines (29-30) and 2-substituted 5(6)-(7-chloroquinolin-4-yl